U.S. PHARMACOPEIA

Search USP29  
Diethylcarbamazine Citrate
Click to View Image
C10H21N3O·C6H8O7 391.42

1-Piperazinecarboxamide, N,N-diethyl-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate.
N,N-Diethyl-4-methyl-1-piperazinecarboxamide citrate (1:1). [1642-54-2].
» Diethylcarbamazine Citrate contains not less than 98.0 percent and not more than 102.0 percent of C10H21N3O·C6H8O7, calculated on the anhydrous basis.
Packaging and storage— Preserve in tight containers.
Identification—
A: It meets the requirements under Identification—Organic Nitrogenous Bases 181.
B: It meets the requirements of the test for Citrate 191.
Water, Method I 921: not more than 0.5%.
Residue on ignition 281: not more than 0.1%.
Heavy metals 231 Dissolve 1.0 g in 20 mL of water. Add 1 mL of 0.1 N hydrochloric acid, dilute with water to 25 mL, and mix: the limit is 0.002%.
Ordinary impurities 466
Test solution: methanol.
Standard solution: methanol.
Eluant: a mixture of methanol and ammonium hydroxide (100:1.5).
Visualization: 16.
Chromatographic purity—
Phosphate buffer, Mobile phase, and Chromatographic system— Proceed as directed in the Assay.
Standard solution— Prepare a solution of USP Diethylcarbamazine Citrate RS in Phosphate buffer having a known concentration of about 0.003 mg per mL.
Test solution— Transfer about 300 mg of Diethylcarbamazine Citrate, accurately weighed, to a 100-mL volumetric flask, add 100 mL of Phosphate buffer, and mix. Filter or centrifuge, and use the clear filtrate or supernatant.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the responses for all the peaks. Calculate the percentage of each impurity in the portion of Diethylcarbamazine Citrate taken by the formula:
10,000(C / W)(ri / rS),
in which C is the concentration, in mg per mL, of USP Diethylcarbamazine Citrate RS in the Standard solution; W is the weight, in mg, of Diethylcarbamazine Citrate taken to prepare the Test solution; ri is the peak response for each impurity obtained from the Test solution; and rS is the peak response for diethylcarbamazine citrate obtained from the Standard solution. Not more than 0.1% of any individual impurity is found.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay—
Phosphate buffer— Dissolve 31.24 g of monobasic potassium phosphate in 1000 mL of water.
Mobile phase— Dissolve 10 g of monobasic potassium phosphate in 1000 mL of water. Prepare a filtered and degassed mixture of 900 mL of this solution and 100 mL of methanol.
Standard preparation— Transfer about 5 mg of USP Diethylcarbamazine Citrate RS, accurately weighed, to a 50-mL volumetric flask, dissolve in and dilute with Phosphate buffer to volume, and mix.
Assay preparation— Transfer about 5 mg of Diethylcarbamazine Citrate, accurately weighed, to a 50-mL volumetric flask, dissolve in and dilute with Phosphate buffer to volume, and mix.
Chromatographic system— The liquid chromatograph is equipped with a 220-nm detector and a 3.9-mm × 15-cm column that contains 5-µm packing L1. The flow rate is about 0.8 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C10H21N3O·C6H8O7 in the portion of Diethylcarbamazine Citrate taken by the formula:
50C(rU / rS),
in which C is the concentration, in mg per mL, of USP Diethylcarbamazine Citrate RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Behnam Davani, Ph.D., MBA, Senior Scientist
Expert Committee : (MDAA05) Monograph Development-Antivirals and Antimicrobials
USP29–NF24 Page 689
Pharmacopeial Forum : Volume No. 28(4) Page 1098
Phone Number : 1-301-816-8394